Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (15)

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 73, Núm. 7, pp. e2026-e2033

2020

  1. Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients

    Journal of acquired immune deficiency syndromes (1999), Vol. 83, Núm. 3, pp. 292-300

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

  2. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

    PLoS ONE, Vol. 13, Núm. 4

  3. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2011

  1. New trends in infective endocarditis

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. SUPPL. 4, pp. 22-35

2007

  1. Update on osteo-articular infections and severe skin and soft tissue infections

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. SUPPL. 1, pp. 28-36

2004

  1. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients

    HIV Clinical Trials, Vol. 5, Núm. 1, pp. 33-39

  2. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis